Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure
Recruiting now · Phase 2
Conditions studied: Acute Respiratory Failure, Hypercoagulability, Fibrinolysis Shutdown
In brief
Patients with coronavirus disease (COVID) and non-COVID acute respiratory failure (ARF) may be at an increased risk of thrombosis due to increased clot formation and decreased clot lysis. This two stage study aims to utilise bedside coagulation technology to detect patients at increased risk and guide tPA treatment to maximise efficacy and safety through a personalised approach.
Key facts
- Study ID
- NCT05540834
- Run by
- South West Sydney Local Health District
- People needed
- 70
- Starts
- 2022-05-18
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2024-04-17
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Acute respiratory failure of primary pulmonary infectious or extrapulmonary infectious aetiology with severity graded by the arterial oxygen partial pressure to inspired fraction of oxygen ratio (P/F) as per the Berlin definition: acute onset of hypoxemia with an arterial partial pressure of oxygen (PaO2) to inspired fraction of oxygen (FiO2) ratio of less than or equal to 300 mmHg with positive end expiratory pressure (PEEP) of 5 cm of water (H2O) or greater
- Requiring admission to Intensive Care
- Aged 18 - 75 years of age
- Procoagulant profile on ClotPro (TradeMark) fibrinogen (FIB)-test +/- extrinsic coagulation pathway (EX)-test - above normal range for amplitude at 10 minutes (A10) and/or maximal clot firmness (MCF) at 30 minutes run time
- Lysis Time on ClotPro tissue plasminogen activator (TPA)-test ClotPro equal to or greater than 365 seconds
You may not qualify if…
- Platelet count <150 x 109/L or a reduction in platelet count of 50% or more in the last 24 hours
- Body weight < 60 kg
- Structural intracranial disease e.g. arterio-venous malformation or aneurysm
- Previous intracranial haemorrhage
- Ischaemic stroke within 3 months
- Traumatic cardiopulmonary resuscitation
- Hypoxaemia from traumatic lung injury
- Active or recent bleeding
- Recent surgery, trauma or invasive procedure
- Systolic blood pressure (BP) > 180 mm Hg
- Diastolic BP > 100 mm Hg
- Pericarditis or pericardial fluid
- Diabetic retinopathy
- Currently menstruating
- Pregnancy - (beta-human chorionic gonadotropin (HCG) to be performed if of child-bearing age)
- Liver failure (known severe liver disease or an alanine aminotransferase or an aspartate aminotransferase level that is 5 times the upper limit of normal)
- Kidney failure (estimated Glomerular Filtration Rate (eGFR =<30 mL/hr or receiving renal replacement therapy)
- Use of therapeutic anticoagulation or platelet antagonists
- Not for active treatment
- Unlikely to survive until the day after tomorrow
Where it is running
- Intensive Care Unit, Liverpool Hospital, South Western Sydney Local Health District — Liverpool, New South Wales, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.